ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Risperidone

Also written as “risperidone”, “Oral risperidone” and “Risperidone ISM 100 mg”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Psychotic Disorders · Autistic Disorder · Dementia, led by 15 companies.

Drug pageRisperidone: every studyMany companies study it; this page follows only the 99 they lead. All 262 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 4, 200399 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only670 open or runningphase 4since Jun 4, 2003May 2, 2002none ahead
Rovi Pharmaceuticals Laboratoriesits history only50 open or runningphase 3since May 12, 2017Feb 5, 2013none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 3since Apr 9, 2018Jan 26, 2009none ahead
AstraZenecaits history only30 open or runningphase 4since Nov 14, 2005May 2, 2002none ahead
Luye Pharma Group30 open or runningphase 1since Jan 31, 2014Jan 31, 2014none ahead
Lyndraits history only30 open or runningphase 3since Mar 9, 2023Sep 16, 2020none ahead
Braeburn Pharmaceuticalsits history only20 open or runningphase 3since May 11, 2016Jan 7, 2016none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Feb 4, 2010Feb 4, 2010none ahead
IPCA Laboratoriesits history only20 open or runningphase 1since Jun 11, 2012Jun 11, 2012none ahead
Sun Pharmaceutical Industriesits history only20 open or runningno phasesince Oct 15, 2010Oct 15, 2010none ahead

Also a collaborator on its studies: Otsuka and H. Lundbeck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Luye Pharma Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 31, 2014First study: phase 1 study in SchizophreniaFirst studyNCT02055287 · 36 enrolled · United States
  2. Mar 18, 2014Phase 1 study in SchizophreniaNCT02091388 · 108 enrolled · United States
  3. Jun 4, 2014Phase 1 study in SchizophreniaNCT02186769 · 16 enrolled · United States

TargetBeta

“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
OlanzapineruleEli Lillyphase 476

Studies

All 3 Luye Pharma Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02186769Schizophrenia · United States1CompletedApr 201516
NCT02091388Schizophrenia · United States1CompletedJan 2015108
NCT02055287Schizophrenia · United States1CompletedJun 201436

How it is read

Names in the registry

  • “risperidone”, 40 entries
  • “Risperidone”, 34 entries
  • “Oral risperidone”, 5 entries
  • “Risperidone ISM 100 mg”, 3 entries
  • “LY03004”, 3 entries

Codes read as this program: LYN005.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.